Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on April 10, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Medical Officer Mark Eisner departing effective April 24, 2026.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Medical Officer Mark Eisner departing effective April 24, 2026
- Successor search underway, creating near-term clinical leadership transition risk
- Eisner’s departure follows notice provided April 7, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.